HK1128929A1 - Pegylated mutated clostridium botulinum toxin - Google Patents

Pegylated mutated clostridium botulinum toxin

Info

Publication number
HK1128929A1
HK1128929A1 HK09108510.5A HK09108510A HK1128929A1 HK 1128929 A1 HK1128929 A1 HK 1128929A1 HK 09108510 A HK09108510 A HK 09108510A HK 1128929 A1 HK1128929 A1 HK 1128929A1
Authority
HK
Hong Kong
Prior art keywords
modified
botulinum toxin
chain
tag
exhibits
Prior art date
Application number
HK09108510.5A
Other languages
English (en)
Chinese (zh)
Inventor
Jrgen Frevert
Volker Specht
Original Assignee
莫茨藥物股份兩合公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 莫茨藥物股份兩合公司 filed Critical 莫茨藥物股份兩合公司
Publication of HK1128929A1 publication Critical patent/HK1128929A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK09108510.5A 2006-03-15 2009-09-17 Pegylated mutated clostridium botulinum toxin HK1128929A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06005300A EP1834962A1 (de) 2006-03-15 2006-03-15 PEGyliertes mutiertes Clostridium botulinum Toxin
PCT/EP2007/002296 WO2007104567A2 (de) 2006-03-15 2007-03-15 Pegyliertes mutiertes clostridium botulinum toxin

Publications (1)

Publication Number Publication Date
HK1128929A1 true HK1128929A1 (en) 2009-11-13

Family

ID=36603470

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09108510.5A HK1128929A1 (en) 2006-03-15 2009-09-17 Pegylated mutated clostridium botulinum toxin

Country Status (17)

Country Link
US (4) US8003601B2 (es)
EP (2) EP1834962A1 (es)
JP (1) JP5232021B2 (es)
KR (1) KR101454273B1 (es)
CN (1) CN101432296B (es)
AT (1) ATE443078T1 (es)
AU (1) AU2007224669B2 (es)
BR (1) BRPI0708907A2 (es)
CA (1) CA2638862A1 (es)
DE (1) DE502007001546D1 (es)
ES (1) ES2334283T3 (es)
HK (1) HK1128929A1 (es)
IL (1) IL193777A (es)
MX (1) MX2008011495A (es)
RU (1) RU2426739C2 (es)
WO (1) WO2007104567A2 (es)
ZA (1) ZA200807284B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
EP2167528B1 (en) * 2007-06-21 2018-01-10 Angelica Therapeutics, INC. Modified toxins
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
EP2719392B1 (en) 2008-06-12 2019-07-24 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of acromegaly
JP5799397B2 (ja) 2008-06-12 2015-10-28 イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 癌の抑制
WO2010022979A1 (en) * 2008-08-29 2010-03-04 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins with altered persistency
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US8993715B2 (en) * 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
WO2011023213A1 (en) * 2009-08-28 2011-03-03 Merz Pharma Gmbh & Co. Kgaa Modified chemodenervating agents
EP2571509B1 (en) * 2010-05-20 2016-07-06 Allergan, Inc. Degradable clostridial toxins
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
PL2952205T3 (pl) 2014-06-06 2018-01-31 Kleiner Fisman Galit Toksyna botulinowa do zastosowania do leczenia paratonii
TWI777260B (zh) 2014-11-07 2022-09-11 美商奇尼塔慢性疼痛有限責任公司 芋螺毒素(conotoxin)肽之修飾及用途
KR102557798B1 (ko) 2014-12-23 2023-07-19 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소 사전충전된 용기
EP3242884B1 (en) 2015-01-09 2021-02-24 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
US9988428B2 (en) 2016-04-19 2018-06-05 Griffon Pharmaceuticals Inc. Pegylated bioactive peptides and uses thereof
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
WO2018236873A1 (en) 2017-06-19 2018-12-27 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIAL INFECTION
AU2018348138A1 (en) * 2017-10-11 2020-04-23 Ambrx, Inc. Porcine G-CSF variants and their uses
BR112020006827A2 (pt) 2018-01-29 2020-10-06 Ipsen Biopharm Limited neurotoxinas botulínicas clivando snare não neuronal
EP3752128A1 (de) * 2018-02-16 2020-12-23 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
WO2019224184A1 (en) 2018-05-21 2019-11-28 Ipsen Biopharm Limited Suppression of bone cancer-induced allodynia
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201815844D0 (en) 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
WO2021150581A2 (en) * 2020-01-21 2021-07-29 Trustees Of Dartmouth College Immunologically optimized botulinum toxin light chain variants
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
WO2024069191A1 (en) 2022-09-30 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxin for use in a treatment of bladder pain syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
AU2002320127A1 (en) * 2001-06-21 2003-01-08 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
EP1784420B1 (en) * 2004-09-01 2008-12-03 Allergan, Inc. Degradable clostridial toxins
EP1834962A1 (de) * 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin

Also Published As

Publication number Publication date
MX2008011495A (es) 2008-09-24
IL193777A0 (en) 2011-08-01
DE502007001546D1 (de) 2009-10-29
US8003601B2 (en) 2011-08-23
US20130156747A1 (en) 2013-06-20
WO2007104567A2 (de) 2007-09-20
CN101432296B (zh) 2014-07-02
RU2426739C2 (ru) 2011-08-20
ZA200807284B (en) 2009-04-29
BRPI0708907A2 (pt) 2011-06-21
US8912140B2 (en) 2014-12-16
AU2007224669A1 (en) 2007-09-20
US20110294747A1 (en) 2011-12-01
US9186396B2 (en) 2015-11-17
US20150166977A1 (en) 2015-06-18
ES2334283T3 (es) 2010-03-08
AU2007224669B2 (en) 2010-05-13
RU2008140368A (ru) 2010-04-20
EP1834962A1 (de) 2007-09-19
EP1994048B1 (de) 2009-09-16
CN101432296A (zh) 2009-05-13
JP5232021B2 (ja) 2013-07-10
IL193777A (en) 2011-09-27
US20090118193A1 (en) 2009-05-07
JP2009531026A (ja) 2009-09-03
WO2007104567A3 (de) 2007-11-01
KR20080106451A (ko) 2008-12-05
CA2638862A1 (en) 2007-09-20
KR101454273B1 (ko) 2014-10-28
US8298550B2 (en) 2012-10-30
ATE443078T1 (de) 2009-10-15
EP1994048A2 (de) 2008-11-26

Similar Documents

Publication Publication Date Title
ZA200807284B (en) Pegylated mutated clostridium botulinum toxin
UA103215C2 (uk) Поліпептид з ксиланазною активністю
WO2007018619A3 (en) Chimeric therapeutic agents
SI2311972T1 (sl) Rekombinantni N-glikozilirani proteini iz prokariontskih celic
UA103216C2 (uk) Поліпептид з ксиланазною активністю
PE20120021A1 (es) Mutantes fgf21
EA200702408A1 (ru) Аналоги глюкагонподобного пептида-2 (glp-2)
MX2009004701A (es) Analogos selectivos del peptido 2 similar al glucagon.
WO2007035600A3 (en) Natriuretic activities
UA94244C2 (ru) Анти-cgrp антагонистическое антитело и фармацевтическая композиция, которая его включает
WO2011068953A3 (en) Atoxic recombinant holotoxins of clostridium difficile as immunogens
TW200722436A (en) A peptide-immunoglobulin-conjugate
WO2009025117A1 (ja) Cdca1ペプチド及びこれを含む薬剤
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
ATE536367T1 (de) Bindende peptidomimetika und deren verwendungen
NZ602702A (en) Modified fgf-21 polypeptides and their uses
WO1999003881A3 (fr) Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
NZ594268A (en) Grass peptides for vaccine
DE602005025141D1 (de) In Zellen eindringende Peptide als Träger für Moleküle
ATE548380T1 (de) Mutante des hgf-precursor-proteins und aktivierte form davon
EP1982992A4 (en) HLA BINDING PEPTIDE, PRE-STEP, DNA DOMAGING AND RECOMBINANT VECTOR
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
WO2006122205A3 (en) Conus californicus neurotoxins
Ghosh et al. A novel method for sequence independent incorporation of activated/protected cysteine in Fmoc solid phase peptide synthesis
EP1915617A4 (en) METHOD AND COMPOSITIONS FOR IDENTIFYING A PEPTIDE WITH INTERMOLECULAR INTERACTION WITH AN INTERESTING OBJECTIVE

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180315